Discontinue treatment in patients developing retinal vasculitis &/or retinal vascular occlusion, typically w/ intraocular inflammation; w/ rhegmatogenous retinal detachment or stage 3 or 4 macular holes. Withhold treatment in case of decrease in best-corrected visual acuity of ≥30 letters compared w/ last assessment; retinal break; subretinal haemorrhage involving center of fovea, or if size of haemorrhage is ≥50% of total lesion area; performed or planned intraocular surgery w/in previous or next 28 days. Not to inj while IOP is ≥30 mmHg. Closely monitor patients experiencing intraocular inflammation at risk of developing retinal vasculitis &/or retinal vascular occlusion. Endophthalmitis, intraocular inflammation, traumatic cataract, retinal detachment & tear; non-ocular haemorrhages & arterial thromboembolic events. Transient increases in IOP w/in 30 min inj w/ vascular endothelial growth factor (VEGF) inhibitors. Bilateral treatment. Potential for immunogenicity; eye pain or increased discomfort, worsening eye redness, blurred or decreased vision, increased number of small particles in vision or light sensitivity. Patients w/ poorly controlled glaucoma; risk factors for retinal pigment epithelial tears; history of stroke, transient ischemic attacks or MI w/in last 3 mth. Diabetic patients w/ HbA1c >10%, proliferative diabetic retinopathy, or uncontrolled HTN. Evaluate patient's medical history for hypersensitivity reactions prior to intravitreal procedure. Monitor & manage increased IOP & optic nerve head perfusion. Concomitant use w/ other systemic or ocular anti-VEGF medicinal products. May affect ability to drive & use machines due to possible temporary visual disturbances. Women of childbearing potential should use effective contraception during treatment & for at least 1 mth after last dose. Not to be used during pregnancy. Not recommended during lactation; not to start lactation for at least 1 mth after last dose. Childn & adolescents <18 yr.
Sign Out
